These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Rasburicase for the treatment of tumor lysis in hematological malignancies. Malaguarnera G, Giordano M, Malaguarnera M. Expert Rev Hematol; 2012 Feb; 5(1):27-38. PubMed ID: 22272702 [Abstract] [Full Text] [Related]
15. Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress. Matuszkiewicz-Rowinska J, Malyszko J. Kidney Blood Press Res; 2020 Oct; 45(5):645-660. PubMed ID: 32998135 [Abstract] [Full Text] [Related]
19. Rasburicase in cancer-related hyperuricemia. Rodriguez M, Campara M, Haaf C. Drugs Today (Barc); 2011 Aug 01; 47(8):591-603. PubMed ID: 21850282 [Abstract] [Full Text] [Related]
20. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique. Darmon M, Vincent F, Camous L, Canet E, Bonmati C, Braun T, Caillot D, Cornillon J, Dimicoli S, Etienne A, Galicier L, Garnier A, Girault S, Hunault-Berger M, Marolleau JP, Moreau P, Raffoux E, Recher C, Thiebaud A, Thieblemont C, Azoulay E, Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique (GRRR-OH). Br J Haematol; 2013 Aug 01; 162(4):489-97. PubMed ID: 23772757 [Abstract] [Full Text] [Related] Page: [Next] [New Search]